Dr Rebecca Weiser

2022

• Mahenthiralingam, E., Weiser, R., Floto, R. A., Davies, J. C. and Fothergill, J. L. 2022. Selection of relevant bacterial strains for novel therapeutic testing. Current Clinical Microbiology Reports 9, pp. 33-45. (10.1007/s40588-022-00182-2)
• Weiser, R. et al. 2022. The lung microbiota in children with cystic fibrosis captured by induced sputum sampling. Journal of Cystic Fibrosis 21(6), pp. 1006-1012. (10.1016/j.jcf.2022.01.006)
• Fischer, R. et al. 2022. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. Journal of Cystic Fibrosis 21(5), pp. 821-829. (10.1016/j.jcf.2022.01.003)

2021

• Al-Amri, M. and Weiser, R. eds. 2021. Proceedings of Cardiff Institute for Tissue Engineering & Repair Annual Scientific Meeting (CITER ASM 2021). Proceedings of Cardiff Institute for Tissue Engineering & Repair Annual Scientific Meeting. Cardiff: Cardiff Institute for Tissue Engineering & Repair, Cardiff University.
• Kelly, S. A. et al. 2021. Antibiotic therapy and the gut microbiome: investigating the effect of delivery route on gut pathogens. ACS Infectious Diseases 7(5), pp. 1283–1296. (10.1021/acsinfecdis.1c00081)
• Weiser, R., Rye, P. D. and Mahenthiralingam, E. 2021. Implementation of microbiota analysis in clinical trials for cystic fibrosis lung infection: experience from the OligoG phase 2b clinical trials. Journal of Microbiological Methods 181, article number: 106133. (10.1016/j.mimet.2021.106133)
• Oakley, J. L. et al. 2021. Phenotypic and genotypic adaptations in Pseudomonas aeruginosa biofilms following long-term exposure to an alginate oligomer therapy. mSphere 6(1), pp. e01216-20. (10.1128/mSphere.01216-20)

2020

• Weiser, R., Yap, Z. L., Otter, A., Jones, B. V., Salvage, J., Parkhill, J. and Mahenthiralingam, E. 2020. A novel inducible prophage from Burkholderia vietnamiensis G4 is widely distributed across the species and has lytic activity against pathogenic Burkholderia. Viruses 12(6), article number: 601. (10.3390/v12060601)

2019

• Cunningham-Oakes, E., Weiser, R., Pointon, T. and Mahenthiralingam, E. 2019. Understanding the challenges of non-food industrial product contamination. FEMS Microbiology Letters 366(23), article number: fnaa010. (10.1093/femsle/fnaa010)
• Weiser, R. et al. 2019. Not all Pseudomonas aeruginosa are equal: strains from industrial sources possess uniquely large multireplicon genomes. Microbial Genomics, article number: 276. (10.1099/mgen.0.000276)

2018

• Ledwoch, K. et al. 2018. Beware Biofilm! Dry biofilms containing bacterial pathogens on multiple healthcare surfaces; a multicentre study. Journal of Hospital Infection 100(3), pp. e47-e56. (10.1016/j.jhin.2018.06.028)

2017

• Song, L. et al. 2017. Discovery and biosynthesis of gladiolin: a Burkholderia gladioli antibiotic with promising activity against Mycobacterium tuberculosis. Journal of the American Chemical Society 139(23), pp. 7974-7981. (10.1021/jacs.7b03382)

2015

• Cullen, L. et al. 2015. Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains. Microbiology 161(10), pp. 1961-1977. (10.1099/mic.0.000155)
• Weiser, R. 2015. The resistance of Pseudomonas aeruginosa to preservatives used in industrial formulations. PhD Thesis, Cardiff University.

2014

• Weiser, R., Donoghue, D., Weightman, A. J. and Mahenthiralingam, E. 2014. Evaluation of five selective media for the detection of Pseudomonas aeruginosa using a strain panel from clinical, environmental and industrial sources. Journal of Microbiological Methods 99, pp. 8-14. (10.1016/j.mimet.2014.01.010)